Aktis Oncology (AKTS) vs CryoPort (CYRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
CryoPort is the larger company by market cap ($852.9 million vs $837.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | CYRX |
|---|---|---|
| Share price | $15.06 | $16.84 |
| Market cap | $837.63M | $852.93M |
| 1-day change | -5.93% | -1.35% |
| YTD return | — | +75.42% |
| 1-year return | — | +66.40% |
| 5-year return | — | -78.30% |
| EPS (TTM) | $-1.70 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $176.18M |
| Revenue growth (YoY) | — | +12.38% |
| Net income (latest FY) | — | $78.30M |
| Gross margin | — | 47.14% |
| Operating margin | — | -20.89% |
| Net margin | — | 44.44% |
| 52-week high | $34.19 | $18.36 |
| 52-week low | $14.72 | $7.61 |
| Distance from 52-week high | -55.95% | -8.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +134.99% | +16.81% |
| Average volume | 361.82K | 629.77K |
| Shares outstanding | 53.75M | 50.65M |
| Employees | 79 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
AKTS vs CYRX FAQ
Which is bigger, Aktis Oncology or CryoPort?
CryoPort (CYRX) is larger, with a market capitalization of $852.93M compared with $837.63M for Aktis Oncology (AKTS).
Are Aktis Oncology and CryoPort in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.